Inside Washington: Reshaping Biotech Drug Development

by Jill Wechsler, BioPharm International FDA is examining policy options for incorporating genomic information into the regulatory process while encouraging manufacturers to share pharmacogenomic research.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

over 22 years ago

Article

Guest Interview: A Strong Dose of Reality: Visiting with Cynthia Robbins-Roth

over 22 years ago

Article

Collaborating Across the Extended Pharmaceutical Enterprise: How Sharing Information Leads to Process Enablement

over 22 years ago

Article

Sialylation Levels Influence Oligosaccharide Quantitation: Analyzing Response Variability Using High-pH Anion-Exchange Chromatography and Pulsed Amperometric Detection

over 22 years ago

Article

SOX in the Boardroom: What the Sarbanes?Oxley Act Means to You

over 22 years ago

Article

The Project Management Institute's Pharmaceutical Specific Interest Group 2002 Benchmark Survey Results: Project Managers and Project Management in the Biotech Industry

over 22 years ago

Article

Small Biopharms Face Unique Challenges: Outsourcing in Early-Stage Drug Development

over 22 years ago

Article

BioTrends: M&A Malaise

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Inside Washington: Reshaping Biotech Drug Development

Articles in this issue

Newsletter

Trending on BioPharm International

How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia

Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs

Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms

Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care